Erythropoiesis Stimulating Agents and Tumor Progression (R21)
The summary for the Erythropoiesis Stimulating Agents and Tumor Progression (R21) grant is detailed below.
This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants.
Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact.
If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Erythropoiesis Stimulating Agents and Tumor Progression (R21): -Purpose. This funding opportunity announcement (FOA), issued by the National Cancer Institute (NCI), invites applications for research projects that investigate the effects of Erythropoietin (EPO) on tumor cell growth. EPO has been widely used to relieve the anemia associated with renal failure. In addition, EPO and other erythropoiesis stimulating agents (ESAs) have recently been used to treat the anemia associated with cancer chemotherapy. However, several clinical trials involving administration of ESAs, have suggested that ESAs may accelerate tumor progression and increase mortality in cancer patients. It is therefore important to understand the biology of ESAs on tumor cell growth and apoptosis. The purpose of this FOA is to stimulate high quality research on the effects of ESAs on tumor cell biology and tumor progression. -Mechanism of Support. This FOA utilizes the NIH Exploratory/Developmental Grant (R21) mechanism and runs in parallel with an FOA of identical scientific scope, PA-09-023 that encourages applications under the NIH Research Project Grant (R01) mechanism. -Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications; therefore, the anticipated number of awards is not known
Federal Grant Title: | Erythropoiesis Stimulating Agents and Tumor Progression (R21) |
Federal Agency Name: | National Institutes of Health |
Grant Categories: | Education Health |
Type of Opportunity: | Discretionary |
Funding Opportunity Number: | PA-09-024 |
Type of Funding: | Grant |
CFDA Numbers: | 93.393 |
CFDA Descriptions: | Cancer Cause and Prevention Research |
Current Application Deadline: | Jan 07, 2012 |
Original Application Deadline: | Jan 07, 2012 |
Posted Date: | Nov 06, 2008 |
Creation Date: | Nov 06, 2008 |
Archive Date: | Feb 07, 2012 |
Total Program Funding: | |
Maximum Federal Grant Award: | $200,000 |
Minimum Federal Grant Award: | |
Expected Number of Awards: | |
Cost Sharing or Matching: | No |
- Applicants Eligible for this Grant
- State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification)
- Additional Information on Eligibility
- Other Eligible Applicants include the following: Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations.
- Link to Full Grant Announcement
- Information not provided
- Grant Announcement Contact
- NIH OER [email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [[email protected]] - Similar Government Grants
- • Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional)
- • Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)
- • National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer ...
- • Sustained Support for Informatics Technologies for Cancer Research and Management (U24 Cli...
- • Early-Stage Development of Informatics Technologies for Cancer Research and Management (U0...
- • Pilot Studies in Pancreatic Cancer
- • Cancer Prevention Research Small Grant Program
- • Molecular Targets for Nutrients in Prostate Cancer Prevention
- More Grants from the National Institutes of Health
- • Feasibility of Novel Diagnostics for TB in Endemic Countries (FEND for TB) (R01 Clinical ...
- • Specialized Programs of Research Excellence (SPOREs) in Cancer Health Disparities and Mino...
- • Strategies for Controlled Release of HIV Vaccines (SCORE-H) (R01 Clinical Trial Not Allowe...
- • NINDS Program Project Grant (P01 Clinical Trial Optional)
- • Centers for Research in Emerging Infectious Diseases (CREID) Network (U01 Clinical Trial N...